RU2019129841A - Частицы pm21 для улучшения хоминга nk-клеток в костном мозге - Google Patents
Частицы pm21 для улучшения хоминга nk-клеток в костном мозге Download PDFInfo
- Publication number
- RU2019129841A RU2019129841A RU2019129841A RU2019129841A RU2019129841A RU 2019129841 A RU2019129841 A RU 2019129841A RU 2019129841 A RU2019129841 A RU 2019129841A RU 2019129841 A RU2019129841 A RU 2019129841A RU 2019129841 A RU2019129841 A RU 2019129841A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- particles
- bone marrow
- contact
- patient
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims 20
- 239000002245 particle Substances 0.000 title claims 8
- 210000001185 bone marrow Anatomy 0.000 title claims 3
- 238000000034 method Methods 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 7
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 2
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 claims 2
- 201000006491 bone marrow cancer Diseases 0.000 claims 2
- 230000033581 fucosylation Effects 0.000 claims 2
- 102100021333 Alpha-(1,3)-fucosyltransferase 7 Human genes 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 101000819497 Homo sapiens Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000007248 cellular mechanism Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (10)
1. Способ переноса NK-клеток в костный мозг, включающий приведение NK-клеток в контакт с одной или более частицами РМ21 и питающими клетками FC21.
2. Способ по п. 1, отличающийся тем, что указанный способ дополнительно включает стимуляцию NK-клеток ИЛ-2, ИЛ-12 и/или ИЛ-18.
3. Способ по п. 1, отличающийся тем, что контакт частиц РМ21 и/или питающих клеток FC21 с NK-клетками происходит до переноса NK-клеток в организм пациента.
4. Способ по п. 1, отличающийся тем, что контакт частиц РМ21 и/или питающих клеток FC21 с NK-клетками происходит после переноса NK-клеток в организм пациента.
5. Способ по любому из пп. 1, 3 или 4, отличающийся тем, что указанный способ индуцирует в NK-клетках клеточный механизм, индуцирующий фукозилирование PSGL-1 на поверхности NK-клеток.
6. Способ по любому из пп. 1, 3 или 4, отличающийся тем, что указанный способ индуцирует в NK-клетках экспрессию FUT7, коррелирующую с фукозилированием PSGL-1 на поверхности NK-клеток.
7. Способ лечения злокачественного новообразования костного мозга или врожденного злокачественного новообразования костного мозга у субъекта, включающий приведение NK-клеток в контакт с частицами РМ21 и/или питающими клетками FC21 и адоптивный перенос NK-клеток в организм субъекта.
8. Способ лечения вирусной инфекции, ассоциированной с костным мозгом, у субъекта, включающий приведение NK-клеток в контакт с одной или более частицами РМ21 и питающими клетками FC21 и адоптивный перенос NK-клеток в организм субъекта.
9. Способ по п. 7 или 8, отличающийся тем, что контакт частиц РМ21 и/или питающих клеток FC21 с NK-клетками происходит до переноса NK-клеток в организм пациента.
10. Способ по п. 7 или 8, отличающийся тем, что контакт частиц РМ21 и/или питающих клеток FC21 с NK-клетками происходит после переноса NK-клеток в организм пациента.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464747P | 2017-02-28 | 2017-02-28 | |
| US62/464,747 | 2017-02-28 | ||
| PCT/US2018/020187 WO2018160673A1 (en) | 2017-02-28 | 2018-02-28 | Pm21 particles to improve bone marrow homing of nk cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019129841A true RU2019129841A (ru) | 2021-03-30 |
| RU2019129841A3 RU2019129841A3 (ru) | 2021-07-06 |
| RU2777993C2 RU2777993C2 (ru) | 2022-08-12 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| IL268945B2 (en) | 2024-05-01 |
| IL309689A (en) | 2024-02-01 |
| KR102811217B1 (ko) | 2025-05-22 |
| WO2018160673A1 (en) | 2018-09-07 |
| CA3057211A1 (en) | 2018-09-07 |
| IL268945B1 (en) | 2024-01-01 |
| KR20240058970A (ko) | 2024-05-07 |
| BR112019017942A2 (pt) | 2020-05-19 |
| MX2024008576A (es) | 2024-07-22 |
| AU2018227801B2 (en) | 2024-02-22 |
| RU2019129841A3 (ru) | 2021-07-06 |
| JP2023093484A (ja) | 2023-07-04 |
| MX2019010249A (es) | 2019-12-16 |
| US20230293585A1 (en) | 2023-09-21 |
| AU2024203371A1 (en) | 2024-06-06 |
| US11696927B2 (en) | 2023-07-11 |
| JP2020509021A (ja) | 2020-03-26 |
| IL268945A (en) | 2019-10-31 |
| CN110612108A (zh) | 2019-12-24 |
| EP3589296A1 (en) | 2020-01-08 |
| AU2018227801A1 (en) | 2019-09-19 |
| US20200061115A1 (en) | 2020-02-27 |
| KR102661091B1 (ko) | 2024-04-26 |
| JP7784089B2 (ja) | 2025-12-11 |
| EP3589296A4 (en) | 2020-09-09 |
| KR20190124268A (ko) | 2019-11-04 |
| SG11201907917XA (en) | 2019-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| IL269380A (en) | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells | |
| MY201637A (en) | Natural killer cells and ilc3 cells and uses thereof | |
| WO2018068008A8 (en) | T cells expressing membrane-anchored il-12 for the treatment of cancer | |
| CA2953584C (en) | Method and apparatus for loading and implanting a shape memory implant | |
| BR112018001298A2 (pt) | copo menstrual | |
| HRP20240798T1 (hr) | Terapija matičnim stanicama kod patologija endometrija | |
| IL276120A (en) | Devices and methods for thermal treatment of tissues | |
| MX2021013368A (es) | Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno. | |
| WO2017048809A8 (en) | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using | |
| HUE072259T2 (hu) | Negatívelektród-lemez, annak elõállítási eljárása, valamint elektrokémiai eszköz | |
| IL290991A (en) | Albalstat for use in the treatment of graft rejection, obliterative bronchiolitis syndrome and graft-versus-host disease | |
| PL3611784T3 (pl) | Materiał czynny elektrody ujemnej, elektroda ujemna zawierająca materiał czynny elektrody ujemnej, akumulator zawierający elektrodę ujemną i sposób wytwarzania materiału czynnego elektrody ujemnej | |
| MY185691A (en) | An asseointegrable device | |
| EA201591522A1 (ru) | Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов | |
| SG11201806177QA (en) | Transplant material for treatment of heart disease | |
| PT3133935T (pt) | Utilização de um extrato de scutellaria baicalensis compreendendo baicalina durante o período de parição para estimular a lactação em animais de criação | |
| MA55794A (fr) | Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk | |
| PL3668272T3 (pl) | Korpus trzymający, urządzenie grzejne i sposób | |
| RU2019129841A (ru) | Частицы pm21 для улучшения хоминга nk-клеток в костном мозге | |
| IL324054A (en) | Pan-ELR+ CXC antibodies as a chemokine for the treatment of hidradenitis suppurativa | |
| WO2015120436A3 (en) | Stat3 phosphorylation during graft-versus-host disease | |
| JP2015000064A5 (ru) | ||
| MY210133A (en) | Compositions and methods for controlled ovarian stimulation | |
| MX2019008627A (es) | Procesos para la preparacion de semillas tratadas. |